title: 90Sr content in 90Y-labeled SIR-spheres and Zevalin.
abstract: Three different 90Y internally administered radionuclide therapies are currently used in both standard-of-care and clinical trial procedures atMD Anderson Cancer Center. TheraSphere and SIR-Spheres therapies utilize 90Y-labeled microspheres, while Zevalin is an 90Y-labeled radioimmunotherapeutic agent. Several publications have indicated radionuclidic impurities resulting from 90Y production methods. The 90Y in SIR-Spheres and Zevalin are produced from a 90Sr/90Y generator, which leaves measurable quantities of 90Sr in the final product. TheraSphere 90Y is produced in a nuclear reactor which results in a large number of impurities, most notably 88Y and 91Y. Product information sheets reference these impurities with specific limits given. These limits represent a tiny fraction of the total product activity, and in the case of TheraSphere and SIR-Spheres gamma-emitting impurities, this has been verified in the literature. An analysis of 90Sr impurities in SIR-Spheres and Zevalin is presented in this paper. Impurity quantities were found to be within the vendors’ documented limits.
authors.affiliation: *Department of Environmental Health and Safety, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030-4009; †Department of Imaging Physics Department, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030-4009.
authors.forename: John
authors.initials: J
authors.lastname: Metyko
authors.forename: William
authors.initials: W
authors.lastname: Erwin
authors.forename: John
authors.initials: J
authors.lastname: Poston
authors.forename: Sandra
authors.initials: S
authors.lastname: Jimenez
mesh_terms: D000911:Antibodies, Monoclonal / Q000737:chemistry*; D005720:Gamma Rays / Q000627:therapeutic use; D005857:Germanium / Q000737:chemistry; D008863:Microspheres; D009688:Nuclear Reactors; D011829:Radiation Dosage; D016499:Radioimmunotherapy / Q000295:instrumentation; D019275:Radiopharmaceuticals / Q000627:therapeutic use; D011878:Radiotherapy / Q000379:methods*; D013326:Strontium Radioisotopes / Q000737:chemistry*; D015021:Yttrium Radioisotopes / Q000737:chemistry*
chemical_list: D000911:Antibodies, Monoclonal; D019275:Radiopharmaceuticals; D013326:Strontium Radioisotopes; D015021:Yttrium Radioisotopes; D005857:Germanium; C422802:ibritumomab tiuxetan